BioCentury This WeekWUSA9
About The Show Meet The Team Program Archive Become a Sponsor
UPDATE FLASH PLAYER AND EXPERIENCE THE NEW BCTV SHOW GUIDE

Mobile Banner Image


      HOME     ABOUT BIOCENTURY     WHY BCTV?     PRESS RELEASES    FREE CONTENT    LINK TO BCTV    CONTACT US   
Advertisement



BIOCENTURY EXTRA LATEST HEADLINES


   TOP STORY

GSK shuffles top management

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) reshuffled its executive management as it prepares to integrate the vaccines business it is acquiring from Novartis AG (NYSE:NVS; SIX:NOVN) in an asset-swapping deal announced in April. The shake-up was announced along with third-quarter earnings (see BioCentury, April 28). more >>

   COMPANY NEWS

Biogen falls on Tecfidera miss

Biogen Idec Inc. (NASDAQ:BIIB) fell $17.70 (5%) to $309.07 on Wednesday after reporting that Tecfidera dimethyl fumarate revenues were $787 million in 3Q14, short of the $800 million consensus estimate. more >>

GSK mulling ViiV IPO

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it is considering an IPO for ViiV Healthcare Ltd., the HIV joint venture it formed with Pfizer Inc. (NYSE:PFE) in 2009. On GSK's third quarter earnings call, CEO Andrew Witty said the company was considering a "partial IPO or IPO of a minority stake," likely no sooner than 2016. more >>

Bavarian Nordic gains on J&J Ebola deal

Bavarian Nordic A/S (CSE:BAVA) gained DKK36.50 (24%) to DKK186.50 after the Crucell Holland B.V. unit of Johnson & Johnson (NYSE:JNJ) paid $25 million up front to license exclusive, worldwide rights to Ebola vaccine MVA-BN Filo. Bavarian Nordic is eligible for $20 million in milestones, plus royalties on commercial sales outside Africa. Concurrently, J&J Development Corp. will acquire a 6.4% stake in Bavarian Nordic for DKK251 million ($43 million) via a private placement of new shares. more >>

NICE draft recommends Xarelto in ACS patients

The U.K.'s NICE issued draft guidance recommending use of Xarelto rivaroxaban from Bayer AG (Xetra:BAYN) in combination with aspirin plus clopidogrel or aspirin alone to prevent blood clots in patients who have acute coronary syndrome (ACS) with elevated cardiac biomarkers. more >>

WuXi licenses Foundation's cancer genomics test

Foundation Medicine Inc. (NASDAQ:FMI) has licensed the laboratory component of its FoundationOne genomic profiling test for solid tumors to WuXi PharmaTech Inc. (NYSE:WX). Oncologists use the laboratory-developed test to identify patients' somatically altered genes and match them with targeted therapies and clinical trials. WuXi's Genome Center in Shanghai, the only CLIA-certified lab in China, will offer the test to companies conducting clinical trials in the country. The companies did not disclose financial terms. more >>

   CLINICAL NEWS

Regulus doubles on interim HCV data

Regulus Therapeutics Inc. (NASDAQ:RGLS) surged $6.98 (103.1%) to $13.75 on Wednesday after announcing interim results from a Phase I trial in which a single 2 mg/kg injection of antisense therapy RG-101 led to significant and sustained viral reductions in HCV-infected patients. more >>

NIH begins second trial of NewLink's Ebola vaccine

NewLink Genetics Corp. (NASDAQ:NLNK) gained $4.01 (12%) to $38.51 on Wednesday after NIH's National Institute of Allergy and Infectious Diseases (NIAID) said it had begun the second Phase I trial of its investigational Ebola vaccine VSV-EBOV (BPSC1001). more >>

   FINANCIAL NEWS

Forendo closes EUR 12M series A

Forendo Pharma Oy (Turku, Finland) closed a EUR 12 million ($15.3 million) series A round led by new investors Novartis Venture Fund and MS Ventures. Existing investors including Karolinska Development AB; Novo Seeds; and Finnvera also participated. more >>

Proteon raises $61.1M in IPO

Proteon Therapeutics Inc. (NASDAQ:PRTO) closed up $0.03 to $10.03 in its first day of trading Wednesday after raising $61.1 million by selling 6.1 million shares at $10 in an IPO on NASDAQ. The price valued Proteon at $149.9 million. Stifel; JMP Securities; Baird; and Oppenheimer are underwriters. more >>

Molecular Partners postpones big Swiss IPO

Ophthalmic and cancer company Molecular Partners AG (Schlieren, Switzerland) postponed plans for a big IPO on the SIX Swiss Exchange, citing "adverse market conditions." The company had begun bookbuilding on Oct. 8 and was scheduled to begin trading today. Last month, it filed to raise CHF125 million ($133.1 million) in the offering. more >>

DBV Technologies launches ADSs

American Depository Receipts for DBV Technologies S.A. (NASDAQ:DBVT; Euronext:DBV) added $1.26 to $22.90 on NASDAQ Wednesday after the allergy company sold 4.3 million ADSs at $21.64 each in a follow-on that, combined with a private placement outside the U.S. and Canada, will raise about $115.8 million. more >>

Advertisement

BIOCENTURY, THE BERNSTEIN REPORT ON BIOBUSINESS

BIOCENTURY, THE BERNSTEIN REPORT ON BIOBUSINESS
COVER STORY

Walking the toll road

Better understanding of biology and new delivery approaches are refreshing interest in TLR modulators.

STRATEGY

Guest Commentary: Paying for cures

A Guest Commentary proposes a framework to help evaluate the value of drugs and define financing options to ensure access.

PRODUCT DISCOVERY & DEVELOPMENT

Beyond knockdown

Alnylam's Phase II patisiran data are the first to validate the company's siRNA platform on a clinically meaningful endpoint.

EMERGING COMPANY PROFILE

Kesios: Reactivating apoptosis

Kesios is targeting tumor-specific NF-kappa B signaling to develop a safer treatment for multiple myeloma.

Rogne: Penetrating peptides

Rogne's topical peptide to treat mild to moderate psoriasis could be safer than topical steroids or injectable biologics.

FINANCE

Sticking with big

Why Canaan is sticking with hybrid venture model for $675M tenth fund

Bicycle pedals on

Bicycle to use £20M to move two bicycle-drug conjugates into clinic for cancer

Raising for Raze

How Atlas built Raze to explore novel mitochondrial metabolism targets in cancer

User Agreement | Terms of Use | Privacy Policy | Your California Privacy Rights | Use of Images

Advertisement